Takeda Partners with Biological E for Dengue Vaccine

Takeda Partners with Biological E for Dengue Vaccine

By, Admin 28 February 2024

Takeda inks partnership with Biological E for 'Make in India' manufacturing for its dengue vaccine

Overview

Takeda inks strategic partnership with Biological E. Limited, the former’s dengue vaccine, TAK-003. The partnership marks a crucial step in the fight against the global public health threat of dengue fever, aligning with the disease-specific target set by the World Health Organization (WHO) to achieve zero case-fatality rate due to dengue by 2030. 

Biological E:  future production

Biological E will scale up its production capacity to potentially reach 50 million doses annually, accelerating Takeda's efforts to manufacture 100 million doses annually within the decade. 

Contribution of Telangana Government

Words from Govt. Leaders

  • Announcing the partnership at BioAsia 2024, a regional life sciences and healthcare forum organized by the Telangana chief minister , Anumula Revanth Reddy, said, ""We are delighted that Hyderabad in Telangana will host the facility where the dengue vaccine, a result of the partnership between Takeda and Biological E., will be manufactured. The state of Telangana offers a conducive R&D and manufacturing environment with a focus on life sciences, particularly vaccines and biologics, and I am delighted that the dengue vaccine production in Hyderabad is aimed at accelerating its access in India and other endemic countries.""
  • "Leveraging Takeda's technological expertise and Biological E's manufacturing capabilities will support greater accessibility and affordability of dengue vaccines, contributing to the nation's healthcare resilience and future preparedness. We are happy to support this partnership among science, government and industry to drive and scale innovations?for universal health coverage,""?said Telangana minister of industry & commerce Duddilla Sridhar Babu.

Words from Takeda

“Our long-term goal for our dengue program has been to make TAK-003 broadly available to those at risk who may benefit from immunization. Within the last year, we've successfully launched in private markets, are now launching in some public programmes, and working with partners to support a broader public health impact,"" said Gary Dubin, M.D., president of the Global Vaccine Business Unit, Takeda. 

Dengue: Epidemiology

  • As the fastest-spreading mosquito-borne viral disease, about half of the world's population is now at risk of dengue. 
  • In India and Southeast Asia, 1.3 billion people live in dengue-endemic areas, with Thailand, India, and Indonesia among some of the most highly endemic countries. 
  • The recent recommendations made by WHO's Strategic Advisory Group of Experts (SAGE) on immunization recommended Takeda's dengue vaccine for introduction in settings with high dengue burden and high transmission intensity to maximize public health impact.

Wods from Dion Warren (Takeda leader) 

"This strategic partnership reaffirms our commitment to supplying vaccines to protect the health of people around the world and our efforts to strengthen partnerships in Asia. With vaccine approvals in Thailand, Indonesia, and recently in Malaysia, we are excited for a future where integrated protection against dengue can potentially improve the lives of countless people in India, Southeast Asia and beyond"", said Dion Warren, Head of India and Southeast Asia Multi-country Organisation, Takeda.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!